Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III Trial of TO-203 in House Dust Mite-induced Rhinitis
jRCT2080221806Phase 3
- Sponsor
- Torii Pharmaceutical
- Start
- May 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing TO-203 with Placebo (2 arms).
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT2080221806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221806.